Search the Newsreel

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The European Commission approved Novo Nordisk A/S' Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related …

Novo Nordisk to launch lower-cost Ozempic copy in South Africa

Novo Nordisk is set to launch a more affordable, authorised copy of its Ozempic diabetes drug, named Extensior, in South Africa on July 27th. This move, in partnership with healthcare company Acino, aims to increase patient access to semaglutide, the active ingredient in Ozempic, …

Novo Nordisk: EU Approval of Wegovy Pill Expands Opportunity, but Cash Pay Raises Systematic Risk

Novo Nordisk received EU approval for its Wegovy pill, expanding its market opportunity, particularly through cash-pay sales in Europe, the US, and UAE. Despite increasing the 2030 sales forecast for the Wegovy pill to $11 billion, Morningstar lowered Novo Nordisk's fair value estimate to …

Novo Nordisk: The Oral Wegovy Promise (NYSE:NVO)

Novo Nordisk has received EU approval for its oral Wegovy pill for weight management, marking the first GLP-1 receptor agonist in pill form cleared for this use in the region. This approval strengthens the company's obesity portfolio and offers patients an alternative to injectable …

PTCL Group Leadership Meets FinVolution at MWC Shanghai 2026 to Explore Credit Technology for Financial Inclusion in Pakistan - PR Newswire APAC

FinVolution Group and PTCL Group met at MWC Shanghai 2026 to discuss leveraging credit technology for financial inclusion in Pakistan. FinVolution, a leading fintech company, showcased its 19 years of experience in AI-powered risk management and digital lending, emphasizing its platform Daira, which is …

Novo secures European approval for oral Wegovy to extend lead over Lilly

Novo Nordisk has received European approval for its oral weight-loss drug, Wegovy (semaglutide), strengthening its lead over competitors like Eli Lilly in the obesity treatment market. This approval follows similar decisions in the US and UK, making oral Wegovy the first and currently only …

Novo's Wegovy pill cleared for weight loss in EU

The European Commission has approved Novo Nordisk’s oral formulation of the weight-loss therapy Wegovy, making it the first oral GLP-1 agonist for obesity and overweight patients in the EU. This approval follows the drug's launch in the UK, UAE, and its existing presence in …

FinVolution Group (FINV) Expands Pakistan Talks, Is The Stock Trading At A Discount?

FinVolution Group (FINV) is exploring expanding its credit technology services into Pakistan after discussions with PTCL Group leaders, amid a recent share price decline despite a positive long-term return. The stock is currently considered 35.4% undervalued, with a fair value of $7.29, driven by …

EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Results

Envoy Medical Inc. reported improved 12-month results from Stage 1 of its pivotal clinical trial for the Acclaim cochlear implant, showing a significant increase in hearing performance compared to baseline and six-month data. Participants achieved a mean CNC word recognition score of 53.2% at …

Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial

Novo Nordisk announced its ongoing Phase 3 clinical study, "Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity." This study investigates a new weekly injectable drug (NNC0487-0111) …

Novo gains head start on Lilly with European Commission approval of Wegovy pill

Novo Nordisk has secured a head start over Eli Lilly in Europe with the European Commission's marketing authorization for the Wegovy pill for obesity and overweight adults. This approval makes it the first GLP-1 receptor available in tablet form in Europe. The European Commission …

Novo Nordisk wins EU approval for Wegovy weight-loss pill

Novo Nordisk has received EU approval for its once-daily Wegovy pill for weight management in adults with obesity or who are overweight, marking it as the first oral GLP-1 weight-loss treatment cleared for use across the EU. The approval, based on clinical trial data …

H.C. Wainwright reiterates Envoy Medical stock rating on trial progress By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $2.50 price target for Envoy Medical (NASDAQ:COCH) after an update on the pivotal trial of its Acclaim cochlear implant. The company announced that the first three patients have completed their 12-month endpoint visits, with topline …

Novo wins EU nod for Wegovy pill and higher-dose Wegovy in single-dose pen

Novo Nordisk has received marketing authorization from the European Commission for its Wegovy pill and a higher-dose version of the Wegovy injectable in a single-dose pen. This approval means the once-daily oral option will be available across 27 EU countries.

NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Novo Nordisk's oral Wegovy has received EU approval for weight management, causing NVO stock to jump 2.5%. This marks the fifth regulatory approval for the oral pill worldwide, and the company plans to launch it in more countries by late 2026. Retail investors have …

Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant

Envoy Medical announced positive 12-month data from Stage 1 of its pivotal clinical trial for the Acclaim® fully implanted cochlear implant, showing significant improvements in speech perception. The study's first 10 participants demonstrated a substantial increase in CNC word recognition scores, with continued improvement …

Novo Nordisk A/S (NVO) extends 30.0% 12-week advance as activity picks up

The healthcare heavyweight is recovering on weekly data, but the setup still lacks clean trend confirmation.

Novo Nordisk A/S (NVO) draws heavier tape as 12-week rebound reaches 30.0%

The healthcare heavyweight is recovering in weekly context, but Relative Strength remains negative and the trend signal has not reactivated.

Previsão PLPL3 — Preço Alvo para 2027

Previsão MELK3 — Preço Alvo para 2027

Plano&Plano (PLPL3): receita cresce +21, mas lucro cai -45%

Plano&Plano (PLPL3): Lucro líquido supera expectativas graças a melhores resultados financeiros

Plano & Plano (PLPL3) tem alta de 39% no lucro no 4º trimestre

Melnick registra queda de 29,6% no lucro líquido do 3T25, mas mantém estabilidade na receita

Melnick (MELK3): BTG mantém compra, apesar de resultados fracos no 3T25

NOVO RESOURCES CORP (NVO.NE) Stock Price, News, Quote & History

Novo Resources Corp (ASX: NVO) Share Price, NVO Stock News, NVO Share Price & Updates

Dados Históricos Melnick Desenvolvimento Imobiliario S.A. - MELK3 | Ações Bovespa | ADVFN Brasil

Análise técnica do Melnick Desenvolvimento Imobiliario SA (BMFBOVESPA:MELK3)